Bolt Biotherapeutics (NASDAQ:BOLT) is a clinical‐stage immuno‐oncology company that focuses on the discovery and development of novel cancer immunotherapies. Founded in 2015 and headquartered in Berkeley, California, Bolt Biotherapeutics has pioneered the design of immune‐stimulating antibody conjugates (ISACs) that selectively deliver potent immunomodulators to the tumor microenvironment. By harnessing proprietary conjugation technology, the company aims to enhance anti‐tumor immune responses while minimizing systemic toxicity commonly associated with conventional immunostimulatory agents.
The company’s lead programs include BDC-1001, an ISAC directed against HER2-expressing tumors, and BDC-2001, targeting prostate‐specific membrane antigen (PSMA) in prostate cancer. These candidates link tumor-specific antibodies to Toll‐like receptor (TLR) agonists, promoting localized activation of antigen-presenting cells and subsequent T‐cell recruitment. Bolt Biotherapeutics also maintains a robust preclinical pipeline exploring additional tumor targets and immunostimulatory pathways, leveraging in‐house expertise in antibody engineering, medicinal chemistry and translational immunobiology.
Bolt operates across North America and Europe, collaborating with leading academic centers and contract research organizations to advance clinical trials and bolster its scientific platform. The company’s development strategy emphasizes strategic partnerships and disciplined trial design, with a view toward achieving meaningful clinical endpoints in solid tumors that have proven resistant to other immunotherapies. Bolt Biotherapeutics also engages with regulatory authorities to align on fast‐track and breakthrough therapy designations, seeking to accelerate patient access to its therapies.
Under the leadership of Chief Executive Officer Lee Kaspar, Ph.D., and Chief Scientific Officer Robert Iannone, M.D., Bolt Biotherapeutics has built a multidisciplinary team of scientists, clinicians and regulatory experts. The management team combines deep experience in oncology drug development, biologics manufacturing and venture‐backed growth, positioning the company to navigate the complexities of late‐stage trials and commercialization. Going forward, Bolt aims to expand its pipeline through both internal innovation and strategic collaborations, with the ultimate goal of delivering transformative immunotherapies to cancer patients worldwide.